CA3078675A1 - Genetic regulation - Google Patents

Genetic regulation Download PDF

Info

Publication number
CA3078675A1
CA3078675A1 CA3078675A CA3078675A CA3078675A1 CA 3078675 A1 CA3078675 A1 CA 3078675A1 CA 3078675 A CA3078675 A CA 3078675A CA 3078675 A CA3078675 A CA 3078675A CA 3078675 A1 CA3078675 A1 CA 3078675A1
Authority
CA
Canada
Prior art keywords
chromosome
responder
interactions
nucleic acids
probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078675A
Other languages
English (en)
French (fr)
Inventor
Alexandre Akoulitchev
Aroul Selvam Ramadass
Ewan HUNTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biodynamics PLC
Original Assignee
Oxford Biodynamics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biodynamics PLC filed Critical Oxford Biodynamics PLC
Publication of CA3078675A1 publication Critical patent/CA3078675A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3078675A 2017-11-03 2018-11-02 Genetic regulation Pending CA3078675A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762581287P 2017-11-03 2017-11-03
US62/581,287 2017-11-03
GBPCT/GB2018/052818 2018-10-03
GB2018052818 2018-10-03
PCT/GB2018/053196 WO2019086898A2 (en) 2017-11-03 2018-11-02 Genetic regulation

Publications (1)

Publication Number Publication Date
CA3078675A1 true CA3078675A1 (en) 2019-05-09

Family

ID=64661410

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078675A Pending CA3078675A1 (en) 2017-11-03 2018-11-02 Genetic regulation

Country Status (13)

Country Link
US (1) US11840737B2 (enExample)
EP (1) EP3704274B1 (enExample)
JP (2) JP2021501592A (enExample)
KR (1) KR102885025B1 (enExample)
CN (1) CN111511930B (enExample)
AU (1) AU2018361833B2 (enExample)
CA (1) CA3078675A1 (enExample)
ES (1) ES2987603T3 (enExample)
HU (1) HUE066292T2 (enExample)
MY (1) MY199800A (enExample)
PL (1) PL3704274T3 (enExample)
SG (1) SG11202003233YA (enExample)
WO (1) WO2019086898A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152645A1 (en) * 2019-09-11 2021-03-18 Oxford BioDynamics PLC Diagnostic chromosome marker
IL296568A (en) * 2020-03-17 2022-11-01 Regeneron Pharma Methods and systems for determining responders to treatment
GB202008269D0 (en) * 2020-06-02 2020-07-15 Oxford Biodynamics Ltd Detecting a chromosome marker
GB202016176D0 (en) * 2020-10-12 2020-11-25 Oxford BioDynamics PLC Disease marker
TW202302862A (zh) * 2021-03-04 2023-01-16 英商牛津生物力學公眾有限公司 染色體交互作用標記物
WO2025215189A1 (en) * 2024-04-12 2025-10-16 Oxford BioDynamics PLC Chromosome marker test

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
GB0603251D0 (en) 2006-02-17 2006-03-29 Isis Innovation DNA conformation
CN101688237A (zh) 2007-01-11 2010-03-31 伊拉兹马斯大学医疗中心 环状染色体构象捕获(4c)
EP2201140A2 (en) 2007-10-15 2010-06-30 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
GB0810051D0 (en) 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
CN102549167B (zh) 2009-05-12 2017-04-26 皇家飞利浦电子股份有限公司 作为前列腺癌标志物的磷酸二酯酶4d7
AU2014275166B2 (en) * 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
WO2015077414A1 (en) 2013-11-20 2015-05-28 Dana-Farber Cancer Institute, Inc. Kynurenine pathway biomarkers predictive of anti-immune checkpoint inhibitor response
JP2018527016A (ja) * 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出

Also Published As

Publication number Publication date
WO2019086898A2 (en) 2019-05-09
JP2021501592A (ja) 2021-01-21
EP3704274B1 (en) 2024-04-17
ES2987603T3 (es) 2024-11-15
CN111511930B (zh) 2024-11-22
AU2018361833B2 (en) 2021-04-22
KR20200081380A (ko) 2020-07-07
AU2018361833A1 (en) 2020-04-30
EP3704274A2 (en) 2020-09-09
JP2023082157A (ja) 2023-06-13
PL3704274T3 (pl) 2024-07-08
SG11202003233YA (en) 2020-05-28
MY199800A (en) 2023-11-23
US11840737B2 (en) 2023-12-12
NZ763540A (en) 2025-03-28
CN111511930A (zh) 2020-08-07
HUE066292T2 (hu) 2024-07-28
US20210230702A1 (en) 2021-07-29
JP7631400B2 (ja) 2025-02-18
WO2019086898A3 (en) 2019-06-13
EP3704274C0 (en) 2024-04-17
KR102885025B1 (ko) 2025-11-11

Similar Documents

Publication Publication Date Title
Xia et al. Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment
US12331357B2 (en) Methods for assessing risk of developing a viral disease using a genetic test
US11840737B2 (en) Genetic regulation of immunoresponse by chromosome interactions
US12234513B2 (en) Methods for assessing risk of developing a viral disease using a genetic test
US12412639B2 (en) Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples
EP3314018A1 (en) Detection processes using sites of chromosome interaction
IL282089B2 (en) A chromosome biomarker
CN109988842B (zh) 一种寡核苷酸标记探针原位检测pdl1的试剂组与应用
US20260112450A1 (en) Methods for selection of cancer patients for anti-angiogenic and immune checkpoint blockage therapies and combinations thereof
AU2020344206B2 (en) Diagnostic chromosome marker
AU2021283746B2 (en) Detecting a chromosome conformation as marker for fibrosis, e.g. scleroderma
WO2025160307A1 (en) Treating cancer using biomarkers and gene signatures
Ammons Use of Single-Cell RNA Sequencing and Comparative Immuno-Oncology to Gain Insights into Spontaneous Canine Cancers
HK40110223A (en) Methods for assessing risk of developing a viral disease using a genetic test
HK40033107B (en) Genetic regulation of immunoresponse by chromosome interactions
HK40033107A (en) Genetic regulation of immunoresponse by chromosome interactions
Mirsafian Gene Expression Signatures of Human Primary Monocytes from Healthy Individuals and XLA Patients Using Deep RNA Sequencing Analysis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231030

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241007

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241025

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250704

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250704

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250806